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Abstract: An elevated serum ferritin level is proposed as a risk factor for coronary heart disease. The role of diabetes mellitus on
serum ferritin levels in myocardial infarction has recently been investigated. The purpose of this study was to assess the effects of
diabetes mellitus on serum ferritin levels in patients with acute myocardial infarction (AMI).
In this study, we studied patients (104 nondiabetic, 26 diabetic patients) with acute myocardial infarction (AMI). AMI was diagnosed
according to typical clinical history, ECG changes and cardiac enzyme elevations. Blood samples for ferritin, iron and total iron
binding capacity (TIBC) and haemogram tests were obtained in the morning within the first 3 consecutive days and were measured
by immunoradiometric assay (IRMA), ferrene assay and ferrozine assay respectively. Whole blood (K3 EDTA as anticoagulant) was
analyzed using Beckman Coulter Hmx hematology. The comparison of groups and subgroups was done using one-way varians
analysis (ANOVA) and Tukey’s Multiple Comparison Test respectively, while the unpaired t test and the Mann Whitney U test were
used for the analysis of the 2 groups and the qualificational data were analyzed using the chi square test .
Serum ferritin levels were significantly increased in the diabetic group. The results were evaluated with a 95% safety margin (P <
0. 05).
In the presence of diabetes mellitus, serum ferritin levels may be elevated, which may increase the risk of coronary heart disease.
Key Words: Ferritin, Diabetes Mellitus, Myocardial Infarction

Introduction
In patients who have had an episode of unstable
coronary artery disease, levels of inflammation markers
such as acute-phase proteins, C-reactive protein, and
fibrinogen tend to be higher, which is the result of an
increase in the risk of cardiovascular disease. Fibrinogen
plays a key role in both coagulation cascade and platelet
aggregation, which is a determinant of plasma viscosity
(1). Free radical species are important agents in both
myocardial ischemic and reperfusion injuries. Superoxide
is capable of releasing iron from ferritin, and the released
iron can cause hydroxyl formation from H2O2 (2).
Most of the ferritin is found in the liver cells, spleen
and bone marrow. It is also found in the heart, pancreas
and kidney. Human serum contains a small but significant
quantity of ferritin. Serum ferritin levels are affected by

age and sex. In normal individuals, ferritin levels are
slightly higher at birth and decrease during childhood
until puberty. After puberty, body iron storage in males
increases progressively with a proportional rise in serum
ferritin, whereas serum ferritin levels are lower and more
stable in females the during reproductive period. Ferritin
levels only increase after the menopause. Literally, may
the difference in hemorheological properties in female
blood is caused by the increased concentration of younger
red blood cells(RBCs) and the reduced population of older
RBCs. Higher viscosity, increased RBC aggregation and
decreased RBC deformability are observed in male
compared with female blood. The Oxygen Delivery Index
(a ratio of hematocrit levels to blood viscosity) is
significantly lower in the male population. There is also a
higher risk of cardiovascular disease due to decreased
oxygen delivery, increased RBC aggregation and
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decreased RBC deformability (3). The normal basal loss
of iron from the body is about 1 mg daily in a 70 kg man
and 0.8 mg in a 55 kg woman.
In myocardial infarction, a gradual increase in serum
ferritin levels can be detected. Furthermore, a significant
increase in ferritin content can be found in peripheral
blood monocytes. May peripheral blood monocytes
activated by steroids during stress could be the cause of
increased serum ferritin levels following AMI (4). There is
a hypothesis that iron depletion improves vascular
dysfunction in type 2 diabetic patients with high ferritin
concentrations (5).
The relationship between inflammation and insulin
resistance has long been accepted . Insulin resistance is
also associated with atheromatous risk factors, such as
central obesity, hyperinsulinemia, hyperglycemia and
hypertriglyceridemia. These are also associated with a
cluster of thrombotic risk factors, notably increased levels
of PAI-1, factor VII, factor XII and fibrinogen. Smoking,
increased body mass and inflammatory responses may
influence the level of serum fibrinogen. Fibrinogen levels
are increased in both type II diabetes and metabolic
syndrome (6). In addition higher iron storage is
associated with an increased risk of type 2 diabetes in
healthy women, independent of known diabetes risk
factors (7). Moreover, increased Hb and ferritin are
associated with gestational diabetes mellitus (8).
Inflammatory processes play a role in the initiation of
unstable coronary artery disease because they destabilize
the atherosclerotic plaque and enhance the formation of
thrombus (9). Several factors may influence the levels of
C-reactive protein and fibrinogen (10, 11).

Materials and Methods
One hundred and four nondiabetic (88 male, 16
female) and 26 diabetic patients (19 male, 7 female) with
acute myocardial infarction (AMI) were examined in this
cross-sectional pilot study. All patients had a typical
history, ECG changes and cardiac enzyme rises relevant to
AMI. All diabetic patients had a type 2 diabetes mellitus
history and had taken antidiabetic agents. According to
ADA-2003, the criteria for the diagnosis of diabetes
mellitus are:
*Symptoms of diabetes plus casual plasma glucose
concentration ≥ 200 mg/dl or
*Fasting plasma glucose ≥ 126 mg/dl or
26

*2-h plasma glucose ≥ 200 mg/dl during an OGTT
Patients were not statistically different in terms of
age. Exclusion criteria from the study were a history of
anemia and/or taking iron preparations on admission. All
patients were admitted to the coronary intensive care unit
within the first 12 h from the onset of the pain. AMI
complications (hypotension, first and second degree block
and complete AV block, arrythmia and heart failure) were
increased in all patients. All patients received parenteral
nitrates, heparin infusion, aspirin (300 mg/day), and
parenteral and oral beta blockers except for those
patients who had contraindications for these medications.
Thrombolytic therapy was administered to patients with
medical indications within the first 24 h (13). Blood
samples for ferritin, iro and total iron binding capacity
(TIBC) and haemogram tests were obtained in the
morning within the first 3 days and were measured by
immunoradiometric assay (IRMA), ferrene assay and
ferrozine assay, respectively. Whole blood (K3 EDTA as
anticoagulant) was analyzed using Beckman Coulter Hmx
hematology analyzer.
The Graph Pad Prisma V.3 packet program was used
for statistical analysis. The comparisons of groups and
subgroups were done using ANOVA and Tukey’s Multiple
Comparison Test, respectively. The unpaired t test, and
the Mann Whitney U test were used for the analysis of
both groups, and qualificational data were analyzed using
the chi square . The results were evaluated with a 95%
safety margin (p < 0.05 level).

Results
According to the demographic data, there was no
statistically significant difference between the diabetic and
nondiabetic groups (P > 0.05 , Table 1). According to the
available data, neither antidiabetic therapy (OAD or
insulin) nor diabetic age have any effect on iron, TIBC or
ferritin levels (P > 0.05 Table 2).
In terms of hemogram parameters, iron and TIBC, no
significant difference was found between the diabetic and
the nondiabetic groups whereas ferritin levels were
higher in the diabetic group (P < 0.05. Table 3).
Although there was no statistically significant
difference between the 2 groups in terms of AMI
localization, the incidence of AMI complications was
higher in the diabetic group (P <0.01 Table 4).
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Table 1. Demographic data.

Age

Nondiabetic group
(n: 104)

Diabetic group
(n: 26)

57.62 ± 12.08

59 ± 9.46

> 0.05
2

Cigarettes

Negative
Positive

60 (57.7%)
44 (42.3%)

10 (38.5%)
16 (61.5%)

X : 3.09
P > 0.05

Hypertension

Negative
Positive

55 (52.9%)
49 (47.1%)

14 (53.8%)
12 (46.2%)

X2: 0.08
P > 0.05

AMI: Acute myocardial infarction

Table 2. Antidiabetic therapies, diabetic age and iron status.

Age
WBC
Hb (g/dl)
HCT (%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)
Diabetic age
WBC
Hb (g/dl)
HCT (%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

OAD (n:18)

Insülin (n: 8)

t

P

58.72 ± 8.29
15894.44 ± 20240.10
14.15 ± 0.77
41.04 ± 3.84
88.68 ± 6.69
183833.33 ± 28520.89
64.72 ± 32.90
348.39 ± 66.62
152.6

59.63 ± 12.32
9612.50 ± 2628.11
12.60 ± 1.72
38.51 ± 5.38
88.65 ± 8.39
200250 ± 60652.99
56.13 ± 35.62
327 ± 42.67
104.55

-0.22
0.87
3.22
1.37
0.01
-0.95
0.60
0.83
0.89

>0.05
>0.05
<0.01
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05

r

P

-0.25
-0.11
-0.05
0.19
-0.04
-0.10
-0.13
0.06

>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05

TIBC: Total iron binding capacity, OAD: oral antidiabetic agents

Table 3. Comparison of the diabetic and nondiabetic AMI groups.

Age
WBC
Hb (g/dl)
HCT (%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

Nondiabetic group
(n: 104)

Diabetic group
(n: 26)

t

P

57.62 ± 12.08
13000 ± 15831.22
13.26 ± 1.89
39.61 ± 7.37
89.84 ± 7.09
187951.92 ± 65515.64
64.92 ± 27..31
343.83 ± 77.40
85.67

59 ± 9.46
13961.54 ± 17007.25
13.67 ± 1.33
40.26 ± 4.42
88.67 ± 7.08
188884.62 ± 40532.78
62.08 ± 33.28
341.81 ± 60.24
135.84

-0.54
-0.27
-1.05
-0.43
0.75
-0.07
0.45
0.12
-1.98

>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
< 0.05

TIBC: Total iron binding capacity
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Table 4. AMI localizations in the diabetic and nondiabetic AMI groups.

AMI localization

AMI complications

Nondiabetic group
(n: 104)

Diabetic group
(n: 26)

Anterior
Inferior
NONQ

44 (44%)
40 (40%)
11 (11%)

14 (53.8%)
6 (23.1%)
6 (23.1%)

X2: 5.58

Negative
Positive

7 (17.9%)
32 (82.1%)

8 (61.5%)
5 (38.5%)

X2: 9.02
P < 0.01

AMI: Acute myocardial infarction

Table 5. Thrombolytic therapy in the nondiabetic group.
Nondiabetic group
Age
WBC
Hb (g/dl)
HCT (%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

SKZ (n: 35)

TPA (n: 6)

MW

P

56.49 ± 10.68
13111.43 ± 17533.34
13.18 ± 1.51
40.93 ± 9.68
90.17 ± 6.90
193200 ± 66379.83
60.86 ± 25.11
338.63 ± 70.07
110.2

41.17 ± 11.53
12433.33 ± 10108.54
13.77 ± 2.38
41.20 ± 6.88
87.02 ± 12.93
225333.33 ± 87257.47
64.50 ± 23.02
346.33 ± 114.65
91.39

34.5
98
86.5
89
101.5
90
95.5
104.5
85.5

<0.01
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05

SKZ; Streptokinase, TPA: Tissue plasminogen activator
Nondiabetic group
Gender
AMI localization

AMI complication

SKZ
Male
Female
Anterior
‹nferior
NONQ
Negative
Positive

30 (85.7%)
5 (14.3%)
13 (38.2%)
19 (55.9%)
2 (5.9%)
4 (23.5%)
13 (76.5%)

TPA
4
2
5
1

(66.7%)
(33.3%)
(83.3%)
(16.7%)

6 (100%)

2
X : 1.31
P > 0.05

X2: 14.22
P > 0.05
X2: 11.70
P > 0.05

SKZ: Streptokinase, TPA: Tissue plasminogen activator

Although nondiabetic patients receiving SKZ therapy
had a higher mean age than those receiving t-PA therapy
(p < 0.01 Table 5), in terms of hemogram parameters,
iron, TIBC, ferritin, AMI localization and AMI complication
no statistically significant difference determined. In
addition, in the diabetic patients the mean ages of both
groups were not statistically different and the hemogram
parameters, iron, TIBC, ferritin, AMI localization and AMI
complications were not statistically different r (P > 0.05,
Tables 5-7).
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Age, hemogram parameters, iron, TIBC and ferritin
levels did not affect AMI localization in the nondiabetic
group (P > 0.05, Table 8). The mean age of the inferiorly
localized patients and that of patients with NON-Q
localization were higher than the mean age of the patients
with anterior localization (P < 0.05).
In terms of TIBC, among patients with anterior,
inferior and NON-Q localization there was no statistically
significant difference, whereas TIBC levels in patients
with NON-Q AMI were higher than the TIBC levels of
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Table 6. Thrombolytic therapy in the diabetic group.
Diabetic group

SKZ (n: 4)

TPA (n: 4)

MW

P

Age
WBC
Hb (g/dl)
HCT(%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

59.75 ± 11.09
33350 ± 41837.66
13.88 ± 0.31
41.75 ± 2.42
83.83 ± 6.74
200250 ± 57314.19
65 ± 27.94
341.75 ± 33.71
189.19

47.25 ± 4.65
9900 ± 920.14
13.95 ± 0.73
41.45 ± 4.04
87.85 ± 4.02
211.750 ± 81846..91
62..50 ± 29..95
327.25 ± 33.69
94.49

2.5
1
6.5
8
4
7
8
7
4

>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05

SKZ; Streptokinase, TPA: Tissue plasminogen activator
Diabetic group

SKZ

TPA

Gender

Male
Female

3 (75%)
1 (25%)

3 (75%)
1 (25%)

X2: 0.01
P >0.05

AMI localization

Anterior
Inferior

2 (50%)
2 (50%)

4 (100%)

X2: 2.66
P > 0.05

AMI complication

Negative
Positive

3 (75%)
1 (25%)

4 (100%)

X2: 1.14
P >0.05

Table 7. Comparison of iron status between thrombolytic therapy positive and negative patients in diabetic and
nondiabetic group.

Nondiabetic group

Diabetic group

Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

Thrombolytic
therapy negative
(n:63)

Thrombolytic
therapy negative
(n: 41)

t

P

67.22 ± 28.91
346.48 ± 78.60
74.03

61.39 ± 24.58
339.76 ± 76.31
136.8

1.07
0.43
-1.63

>0.05
>0.05
>0.05

Trombolytic
therapy negative
(n:18)

Trombolytic
therapy negative
(n:8)

61.33 ± 36.47
345.06 ± 69.82
136.8

63.75 ± 26.85
334.50 ± 32.15
133.7

-0.17
0.41
0.05

>0.05
>0.05
>0.05

patients with inferior AMI (P < 0.05). In the diabetic
group no significant difference was found between the
anterior and inferior AMI groups in terms of ferritin
levels. Ferritin levels in the patients anterior and inferior
AMI groups were significantly higher than the ferritin
levels of the NON-Q AMI patients (P< 0.01, Tables 9,
10).

In the nondiabetic group hemoglobin (P< 0.0001)
hematocrit (P < 0.05) and ferritin (P < 0.001) levels
were significantly higher in females, whereas sex did not
affect the hemoglobin, hematocrit and ferritin levels in
the diabetic group (Table 11). In addition, sex had no
effect on iron, ferritin or TIBC in either groups (P> 0.05,
Table 12). Although no significant effect of hypertension
29
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Table 8. Ferritin and AMI localizations in the nondiabetic AMI group.
Anterior (n: 46)

Inferior (n: 42)

NONQ (n: 16)

F

P

Age

57.84 ± 11.52

56.15 ± 12.94

60.55 ± 10.94

0.71

>0.05

WBC

14256.82 ± 18381.49

10720 ± 5165.68

20063.64 ± 30315.81

1.22

>0.05

Hb (g/dl)

13.25 ± 1.88

13.29 ± 1.90

12.21 ± 2.05

2.00

>0.05

HCT (%)

38.88 ± 5.39

40.84 ± 9.77

36.67 ± 5.61

1.07

>0.05

MCV (fl)

89.47 ± 7.82

89.94 ± 7.39

89.70 ± 5.03

0.21

>0.05

PLT

189022.73 ± 61598.28

187750 ± 68055.69

186727.27 ± 66059.20

0.12

>0.05

Iron (µ/dl)

62.20 ± 25.13

68.13 ± 31.53

55.82 ± 17.81

1.60

>0.05

TIBC (µ/dl)

345.20 ± 80.18

342.83 ± 72.45

358.36 ± 42.55

0.15

>0.05

100.62

84.63

57.11

0.88

>0.05

Ferritin (ng/ml)

FE: iron, TIBC: Total iron binding capacity, anterior myocardial infarction, inferior myocardial infarction, NONQ: non-Q myocardial
infarction

Table 9. Ferritin and AMI localizations in the diabetic AMI group.
Anterior (n: 14)

Inferior (n: 6)

NONQ (n: 6)

F

P

Age

54.79 ± 10.24

63.50 ± 6.38

64.33 ± 5.09

3.669

<0.05

WBC

11642.86 ± 3690.47

23450 ± 35571.38

9883.33 ± 1565.14

1.262

>0.05

Hb (g/dl)

13.84 ± 0.78

13.20 ± 1.47

13.75 ± 2.18

0.483

>0.05

HCT (%)

40.86 ± 3.82

37.45 ± 5.14

41.67 ± 4.50

1.748

>0.05

MCV (fl)
PLT

89.12 ± 5.56

85.93 ± 9.88

90.37 ± 7.74

0.629

>0.05

199928.57 ± 51718.86

178833.33 ± 16916.46

173166.67 ± 14648.09

1.171

>0.05

Iron (µ/dl)

56.14 ± 23.01

50.50 ± 21.39

87..50 ± 51.66

2.643

>0.05

TIBC (µ/dl)

334.07 ± 48.25

308.50 ± 64.48

393.17 ± 57.20

3.979

<0.05

182..34

197.08

47.10

6.341

<0.01

Ferritin (ng/ml)

TIBC: Total iron binding capacity, anterior myocardial infarction, inferior myocardial infarction, NONQ: non-Q myocardial infarction

Table 10. Comparison of age ,TIBC, ferritin levels in the diabetic group.
Age

TIBC (µ/dl)

Ferritin (ng/ml)

P < 0.05

P > 0.05

P > 0.05

Anterior/NONQ

P < 0.05

P > 0.05

P < 0.01

Inferior/NONQ

P > 0.05

P < 0.05

P < 0.01

Anterior/Inferior

or smoking on iron, TIBC or ferritin levels was observed
in the diabetic group (P> 0.05), Iron levels were higher
(P < 0.05) in hypertensive and smoking patients in the
nondiabetic group (Table 13).
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Discussion
Hughes K et al. evaluated cardiovascular risk factors
in type 2 and non-diabetics among Asians in Singapore.
This study showed that females with type 2 diabetes
mellitus (DM) had higher mean serum fibrinogen levels
compared with nondiabetics, which could explain the
greater cardiovascular effect of DM in females than in
males. Mean levels of serum ferritin were higher in the
type 2 DM group than in the control group (14). They
also found that smoking was unrelated to serum ferritin
levels. In our study, we found higher Hb, Hct and ferritin
levels in males compared with females within the
nondiabetic AMI group (P < 0.001). In the diabetic AMI
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Table 11. Body iron status in male and female patients in two groups.
Nondiabetic
Age
WBC
HGB (g/dl)
HCT (%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)
Diabetic
Age
WBC
Hb (g/dl)
HCT (%)
MCV (fl)
PLT
Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

Male (n: 88)

Female ( n: 16)

t

P

57.49 ± 11.86
12088.64 ± 13397.82
13..57 ± 1.74
40..38 ± 7..56
91 ± 5.87
184943.18 ± 62989..21
64.85 ± 28..35
340.76 ± 80.24
100..2

58.31 ± 13.64
18012.50 ± 25459.61
11.58 ± 1.83
35.41 ± 4.38
83.05 ± 9.70
204500 ± 78206.56
65.31 ± 21.42
360.69 ± 58.58
36..55

-0.25
-1.38
4.17
2.54
0.44
-1.10
-0.06
-0.95
3.40

>0.05
>0.05
<0.0001
<0.05
>0.05
>0.05
>0.05
>0.05
<0.001

Male (n: 19)

Female (n: 7)

t

P

57.16 ± 9.78
10784.21 ± 3324.70
13.84 ± 1.19
40.46 ± 4.27
89.83 ± 6.11
190894.74 ± 44286.81
61.95 ± 33.27
338.11 ± 60.62
160.28

64 ± 6.76
22585.71 ± 32454.45
13.23 ± 1.68
39.71 ± 5.11
85.53 ± 9.02
183428.57 ± 30231.65
62.43 ± 35.97
351.86 ± 62.75
86.69

-1.70
-1.62
1.04
0.38
1.40
0.41
-0.03
-0.51
1.43

>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05

Table 12. Comparison of iron status between males and females in the diabetic and nondiabetic AMI
groups.

Male

Female

Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

Iron (µ/dl)
TIBC (µ/dl)
Ferritin (ng/ml)

Nondiabetic group
(n: 88)

Diabetic group
(n: 19)

t

P

64.85 ± 28.35
340.76 ± 80.24
100.2

61..95 ± 33..27
338.11 ± 60.62
160..28

0.39
0.14
-1.77

>0.05
>0.05
>0.05

Nondiabetic group
(n: 16)

Diabetic group
(n: 7)

65.31 ± 21.42
360.69 ± 58.58
36..55

62.43 ± 35..97
351.86 ± 62.75
86.69

0.24
0.33
-1.65

>0.05
>0.05
>0.05

group we found no statistically significant difference
between males and females. When we compared the 2
groups in terms of body iron status and gender, we again
found no statistically significant differences between
diabetic and nondiabetic males and females. This result is
in agreement with those in the literature.. There were no
statistically significant differences in terms of serum iron
or TIBC between the 2 groups. When we compared the 2
groups, we found that the serum ferritin level was

significantly increased in the diabetic MI group (P< 0.05).
We also evaluated smoking and hypertension as having no
effect on serum ferritin levels, again in agreement with
the literature.
Oba et al. showed that the mean serum ferritin,
glycosylated ferritin and non-glycosylated ferritin levels in
serum were significantly higher in older patients (age
>60) with retinopathy compared with those in healthy
controls. Our results suggest that diabetic
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Table 13. Comparison of iron status in smokers versus nonsmokers and hypertensive versus normotensive
patients in diabetic and nondiabetic myocardial infarction groups.

Nondiabetic group

Nonsmoker
(n: 60)

Smoker
(n: 44)

t

P

Iron (µ/dl)

59.22 ± 25.19

72.3 ± 28.63

-2.41

<0.05

TIBC (µ/dl)

333.7 4 ± 83.68

357.59 ± 66.38

-1.56

>0.05

101.74

67.77

1.80

>0.05

Nonsmoker
(n: 10)

Smoker
(n: 16)

Iron (µ/dl)

68.90 ± 41.77

57.81 ± 27.37

0.82

>0.05

TIBC (µ/dl)

316.70 ± 58.84

357.5 ± 57.35

-1.74

>0.05

188.71

110.61

1.35

>0.05

HT (-)
(n: 55)

HT (+)
(n: 49)

Iron (µ/dl)

62.65 ± 25.62

67.47 ± 29.14

-2.41

<0.05

TIBC (µ/dl)

338.29 ± 79.14

350.04 ± 75.73

-1.56

>0.05

77.48

95.90

1.80

>0.05

HT (-)
(n: 14)

HT (+)
(n: 12)

Iron (µ/dl)

70.36 ± 42.29

52.42 ± 14.64

0.82

>0.05

TIBC (µ/dl)

346.64 ± 65.63

336.17 ± 55.61

-1.74

>0.05

85.75

232.33

1.35

>0.05

Ferritin (ng/ml)

Diabetic group

Ferritin (ng/ml)

Nondiabetic group

Ferritin (ng/ml)

Diabetic group

Ferritin (ng/ml)

microangiopathy is associated with abnormal increased
ferritin levels in serum. They also determined that none
of these values differ in patients with or without
macroangiopathy or in healthy controls (15). Canturk et
al. evaluated the association between serum ferritin
concentrations and diabetes mellitus complications in 329
patients and 269 healthy controls. They found a
correlation between ferritin levels and diabetic
retinopathy (16). However, in our study serum ferritin
levels were significantly increased in the diabetic AMI
group (P< 0.05). This result suggests that patients with
diabetic macroangiopathic complications like AMI, had
higher serum ferritin levels in our series. We did not
compare serum ferritin levels in diabetic microvascular
complications because we did not evaluate other
complications of diabetes mellitus.

32

Epidemiological evidence concerning the role of iron,
a lipid peroxidation catalyst, in coronary heart disease is
inconsistent. A study from Eastern Finland, performed by
Toumainen et al. involved 99 men with an AMI history
and 98 controls during 6.4 years of follow up, this
showed an association between increased body iron
stores and increased risk of AMI (17). In addition, Halle
et al. demonstrated that increased serum ferritin
concentrations between 200 and 500 mg/l are a strong
risk factor for acute myocardial infarction in Finnish men,
although they could not account for this association.
However, the findings are thought to show a correlation
between serum ferritin and insulin resistance syndrome
factors in the Finnish population. They assumed an
association between ferritin and an atherogenic LDL sub
fraction profile, a result that could n explain the observed
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relationship between ferritin and atherosclerosis. They
found that men with moderately higher ferritin levels had
a significantly worse coronary risk profile than men with
lower levels (18).
In the literature mean serum ferritin levels were
higher in men and postmenopausal women who had a
higher risk of atherosclerosis than did the corresponding
controls (19). In addition thrombolytic therapy may have
an effect on serum ferritin levels in patients with AMI.
Cottin et al. determined the importance of the temporal
relationship between lipid peroxidation and iron status
after thrombolytic therapy in 17 men with myocardial
infarction. The peak iron level was observed at 9.4 ± 7.3
h after thrombolytic therapy, and this returned to the
pre-reperfusion levels at 48 h (2). In our study, there was
no difference in ferritin levels between TPa and SKZ
within the diabetic and nondiabetic groups. There was
also no statistically significant difference between diabetic
and nondiabetic MI groups who received or did not
receive thrombolytic therapy. In our study serum ferritin
levels were highest in inferior MI, anterior MI and non-Q
MI among diabetic patients, in that order yet we found no
differences in terms of MI localization and serum ferritin
levels compared with nondiabetic patients. Another study,
on type I diabetic men, by Carenini et al. showed that
hyperglycemia does affect the range of enzymatic
glycosylation of serum ferritin (20). Our patients were all
type 2 diabetics so we were not able to compare the 2
diabetic types in terms of iron status.

significant associations found between body iron stores
and the risk of coronary heart disease. In that prospective
study, 38244 healthy men (blood donors) were examined
over 4 years of follow up (22). In the Rotterdam study it
was shown that are other risk factors like diabetes,
smoking, hypercholesterolemia or serum ferritin may
adversely affect ischemic heart disease risk in older
patients (23). We could not find any relationship between
body iron status and age. Antidiabetic agents (insulin and
oral antidiabetics) have no effect on ferritin levels. We
could not find any significant differences between
smokers and nonsmokers in either group. Interestingly
serum iron levels showed a statistically significant
increase in smokers and hypertensive patients within the
nondiabetic MI group (P < 0.05).
Armaganijan et al. showed that the serum levels of
ferritin and other organic iron indicators (transferrin
saturation, TIBC, hemoglobin and hematocrit) were
neither risk factors nor risk markers for coronary
atherosclerosis. Moreover, they demonstrated that serum
iron levels were higher in the group without
atherosclerosis (24).

Conclusion
Men with type 2 diabetes have increased serum
ferritin levels and this condition may adversely affect the
risk of coronary heart disease in this population.

There are some epidemiologic studies, that do not
support the hypothesis of a relationship between iron and
heart disease risk. For example, in an NHANES study (21)
that included 1604 patients without CHD, no statistically
significant associations between serum ferritin and
coronary heart disease were found. In another
prospective study, by Ascherio et al. there were no
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